David McIntosh: The Evolving Safety Framework for Plasma-Derived Therapies
David McIntosh, Founder and Chair of United Plasma Action, shared Plasma Protein Therapeutics Association’s post on LinkedIn:
“This interesting piece of work will be of significant interest to anyone working in, or interested in, this field of life-saving medicines.
A footnote to add is that what is being described is the 80 percent of current World supplies of plasma that are achieved via Voluntary Reasonably Compensated Donation (VRCD).
Plasma obtained via so-called ‘Unpaid Donation’ almost certainly generates similar results, but as there is so much less of it in the World, relevant data is more scarce.
What is certainly clear, from the vast body of evidence gathered throughout the years of this Century, is that VRCD plasma collection is as safe as, if not safer than, unpaid donor plasma.
As safe – and much more of it – is surely a winning formula!”
Plasma Protein Therapeutics Association (PPTA) shared a post on LinkedIn about a recent article by Halide Tuna et al, published in Annals of Blood, adding:
“A new peer-reviewed publication authored by PPTA’s Halide Tuna and Dr. Toby Simon explores how plasma-derived medicinal products have achieved today’s strong safety profile.
The publication in Annals of Blood highlights the evolution of the ‘safety tripod’ — donor screening, testing, and pathogen reduction — and its role in ensuring the continued safety of plasma-derived therapies.
The conclusion is clear: strong, science-driven systems continue to protect patients today, while ongoing surveillance, periodic evaluation of methods, and technological innovations are essential for future preparedness.”
Title: Plasma-derived medicinal products: a narrative review of the multi-layered approach to ensuring pathogen safety
Authors: Halide Tuna, Toby Simon
Other posts featuring David McIntosh on Hemostasis Today.
-
Sep 30, 2026, 01:52Javed Anees: DADA2 – When a Young Stroke Is More Than a Stroke
-
Sep 30, 2026, 01:51How a Venous Thrombus Becomes Revascularized – ISTH
-
Sep 29, 2026, 22:45Victor Agunyego: Paracetamol – The Most Common Drug We Underestimate
-
Sep 29, 2026, 22:42Nova Sinclair: Advancing the Future of Hematology – Meet Our 2027 Organizing Committee
-
Sep 29, 2026, 22:41Lorenz Räber: Intracoronary Imaging in PCI – Why, When, How, and Which Modality?
-
Sep 29, 2026, 22:31Selma Turkovic: Pleased to Deliver the Opening Presentation at Kingston Hospital
-
Sep 29, 2026, 22:31Miguel Teran: Ultrasound and Simulation in Arterial Blood Sampling
-
Sep 29, 2026, 22:28Mohammad Refaei: Navigating Your Career in Hematology From Training to Practice
-
Sep 29, 2026, 22:27Matteo Foschi: 10 Clinical Pearls for Antithrombotic Therapy in Secondary Stroke Prevention